Latest Headlines

Latest Headlines

LigoCyte rounds up $28M in third round

Bozeman, MT-based LigoCyte Pharmaceuticals has rounded up $28 million in its third round of venture capital. The money will be used for the clinical development of two lead vaccines targeting

Insurance fears make volunteers balk at AIDS trial

A professor at the University of Toronto is warning that researchers may find it increasingly difficult to enlist volunteers for new trials exploring the safety and efficacy of experimental AIDS

Cytos' blood pressure vax data shows new approach

New data from a small human study of Cytos' blood pressure vaccine has stirred

NanoBio gets fresh backing for vaccine program

The venture capital group Perseus has pumped $10 million dollars into NanoBio, bringing its total investment in the University of Michigan spin-off to $30 million. The developer has been working on

Japanese R&D team targets next gen flu jabs

Investigators in Japan have designed a new vaccine that has been effective in animal tests against multiple strains of influenza, including varieties of the dread bird flu. Using a peptide derived

GSK bird flu vaccine provides more positive data

New trial data on GlaxoSmithKline's experimental bird flu vaccine indicates that the drug works against a variety of subsets of the virus. A trial that recruited volunteers in Hong Kong, Taiwan,

Malaria trials will pay volunteers to get infected

The PATH Malaria Vaccine Initiative and Seattle Biomedical Research Institute are teaming up on a new testing facility devoted to preventing malaria. When the Seattle building is complete in two

Out with old, in with new smallpox vaccine

With a new smallpox vaccine accumulating in federal stockpiles, the U.S. government is disposing of millions of doses of Dryvax, the old smallpox vaccine that relies on skin scrapings from infected

Whistleblowers allege problems with Wyeth's Prevnar

Two former Wyeth workers continue to cause controversy for Wyeth's blockbuster vaccine Prevnar. Wyeth disclosed recently that the workers' whistleblower suits accused the company of making false

Novartis opens non-profit R&D vaccine center

One of the world's biggest pharma companies is breaking its business mold for its new R&D center for vaccines. Novartis is modeling its new vaccine development center in Italy on the Novartis